We are live on ! Find out more
TRIB

Trinity Biotech

26 hedge funds and large institutions have $10.8M invested in Trinity Biotech in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% less ownership

Funds ownership: 2.21%2.17% (-0.04%)

10% less funds holding

Funds holding: 2926 (-3)

16% less capital invested

Capital invested by funds: $12.9M → $10.8M (-$2.1M)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
26
Holders Change
-3
Holders Change %
-10.34%
% of All Funds
0.51%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
5
Reduced
6
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Verition Fund Management
26
Verition Fund Management
Connecticut
-$15K -2,418 Closed
Deutsche Bank
27
Deutsche Bank
Germany
-$9K -1,496 Closed
JCM
28
Jacobi Capital Management
Pennsylvania
-$2K -400 Closed

TRIB Hedge Fund Activity: Q4 2019 in Review

26 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2019, worth a combined $10.8M — down 16% from $12.9M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TRIB and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 5 added.

The largest buyer was Fondren Management, adding an estimated $208K. The largest seller was Janus Henderson Group, exiting entirely with an estimated $884K sold.

  • 26 institutional investors held Trinity Biotech (TRIB) as of Q4 2019, down from 29 in Q3 2019.
  • Funds reported $10.8M of Trinity Biotech stock for Q4 2019, down 16% quarter-over-quarter.
  • 4 funds opened new Trinity Biotech positions in Q4 2019 and 7 closed out, a net change of -3 holders.
  • The largest Trinity Biotech buyer in Q4 2019 was Fondren Management, an estimated $208K added.
  • The largest Trinity Biotech seller in Q4 2019 was Janus Henderson Group, an estimated $884K sold.

Based on aggregated 13F filings for Q4 2019.